USPTO 2015–2025 USPTO PatentsView US Corporation

4D Molecular Therapeutics Inc.

USPTO PatentsView assignee record - 15 granted patents across 5 technology areas, recorded in grant years 2021–2023. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C12N (MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA).

The verdict

According to USPTO PatentsView, 4D ranks #18,333 of 50,000 tracked US assignees by granted-patent volume, with 15 patents across 5 technology areas.

#18,333
of 50,000 US assignees by volume
Top 19%
by Innovation Score (47.1/100)
18.9
avg claims per patent

USPTO PatentsView assignee plate

Corpus R18333 · US Corporation #18,333 · 15 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-PAR · CLAIMS-RICH · TYPE-USCORP · SPAN-YRS · BOOK-RICH

  • GRANTS-MICRO 15 grants
  • MID-PACK #18,333/50,000
  • PHOTO-FINISH 138 East LCD Advance…
  • CPC-NARROW C12N · 5 areas
  • INNOV-PAR 47.1/100
  • CLAIMS-RICH 18.9 claims/avg
  • TYPE-USCORP US Corporation
  • SPAN-YRS 2021–2023 · 3y
  • BOOK-RICH 9/10 fields

Nearest grant-volume peer: 138 East LCD Advancements Limited (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Innovation-score neighbourhood around 4D

Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.

score

What this shows 4D Molecular Therapeutics Inc. stamps GRANTS-MICRO, MID-PACK, PHOTO-FINISH, CPC-NARROW, INNOV-PAR, CLAIMS-RICH, TYPE-USCORP, SPAN-YRS, BOOK-RICH. Volume places it #18,333 of 50,000; Innovation Score 47.1/100 sits in the top 19% of the PatentsView-derived corpus. Closest grant-volume peer on this plate is 138 East LCD Advancements Limited (±0 grants).

Source USPTO PatentsView, PlainPatent Innovation Score As of 2015–2025

Portfolio overview

4D Molecular Therapeutics Inc. has been granted 15 US utility patents between 2021 and 2023, placing 4D Molecular Therapeutics Inc. at #18,333 of 50,000 across all assignees tracked by PlainPatent. This portfolio spans 5 distinct Cooperative Patent Classification (CPC) subclasses, averaging 18.9 claims per patent with primary concentration in C12N (MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA). As a US Corporation, 4D Molecular Therapeutics Inc. is one of the more focused assignees in the PatentsView dataset. By volume, 4D sits between Istreamplanet Co., Llc (16 patents, rank #18,329) and Academy OF Shenzhen Guohua Optoelectronics (15 patents, rank #18,337) - the closest US assignees by grant volume. The composite Innovation Score of 47.1/100 blends portfolio volume, grant velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Grant cadence records the difference between two grant-year windows. Historical data spans 2021 through 2023, with 15 total grants over that period. Grant timing can lag the related application by years, so this comparison does not establish current R&D spending, strategic intent, or a company’s application activity. The US Corporation classification provides context for the assignee record, not a conclusion about its business strategy.

Claim depth and technology breadth describe this aggregate record. 4D Molecular Therapeutics Inc.'s 18.9 average claims per patent is an average count, not a measure of claim scope, legal strength, enforceability, or design-around risk. The record spans 5 CPC subclasses. Combined with portfolio volume, these figures let readers compare the documented grant records of assignees in similar technology classes.

Who files at 4D's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows 4D holds 15 patents at rank #18,333, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near 4D

By rank, the assignees closest to #18,333 in granted patent volume.

Leaders in C12N (Microorganisms OR Enzymes)

Other assignees with the most granted patents in 4D's primary technology class.

4D's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

47 Top 19% higher than 81% of 50,000 US assignees

0–10: 687 US assignees (1%). Below this entry. 10–20: 2,527 US assignees (5%). Below this entry. 20–30: 13,162 US assignees (26%). Below this entry. 30–40: 15,294 US assignees (31%). Below this entry. 40–50: 11,491 US assignees (23%). This entry sits in this band. 50–60: 5,058 US assignees (10%). Above this entry. 60–70: 1,537 US assignees (3%). Above this entry. 70–80: 234 US assignees (0%). Above this entry. 80–90: 10 US assignees (0%). Above this entry. 90–100: 0 US assignees (0%). Above this entry. This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

3.544.555.566.5 202120222023 5
USPTO utility patent grants by year · 2021–2023

Grants by year

Teal-shaded recent years (2020–present) versus the 2021–2019 baseline. Full figures in the table below.

View data table
4D Molecular Therapeutics Inc. patent grants by year, 2015–2025
Year Patents Granted Share of Period
2021 4 26.7%
2022 6 40.0%
2023 5 33.3%

Where it ranks

Overall rank by patents

#18,333

of 50,000 tracked assignees

Innovation Score

47.1 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.